An outstanding week for chimeric antigen receptor T cell (CAR-T) therapy companies, between Gilead Sciences Inc.'s $11.9bn purchase of Kite Pharma Inc. and US FDA approval for Novartis AG's Kymriah (tisagenlecleucel), could turn into a great run for cell therapy developers.
Gilead's Kite acquisition showed that big pharma and large biotech companies see significant commercial value in CAR-T therapies – enough...








